Doctor of Pharmacy Candidate 2024
The University of Texas at El Paso
Jordan Winfield is a Pharm.D. candidate at the University of Texas at El Paso School of Pharmacy. Jordan earned both his Bachelor's and Master’s degrees in Biological Sciences at the University of Texas at El Paso. His research interests are in the fields of translational science and clinical pharmacology, specifically in the realm of advancing drug development for solid tumors and addressing the complexities of HIV-related cancers. With a particular emphasis on identifying biomarkers for targeted therapy involving immune checkpoint inhibitors, antibody-drug conjugates, and Bispecific T-cell Engagers (BiTEs); his goal is to optimize the efficacy and safety of therapeutic modalities through the application of PK/PD modeling.
Jordan’s Master's thesis project focused on characterizing the antiviral activity of SLFN13. This involved a comprehensive exploration, from DNA sequence alignment to assessing protein expression in various cell lines and uncovering the regulation of SLFN13 through lysosomal degradation. This work has been submitted as an abstract to the University of Texas at El Paso Couri symposium and is part of a manuscript being written to characterize the SLFN family of proteins.
During his Doctor of Pharmacy studies, Jordan collaborated on significant projects such as p53-Nitrosylation in Drug-Resistant Melanoma. These findings were presented at the AACR 2023 Annual Conference, highlighting the profound impact on p53's DNA-binding activities and downstream gene expression. Jordan's ongoing project on CDK 4/6 Inhibitor drug-resistant breast cancer uses a multidisciplinary approach to explore resistance mechanisms, investigate therapeutic combinations, and develop preclinical PK/PD models.
For the ASCPT 2024 annual meeting, he reviewed the clinical progress of therapeutics targeting the adenosine pathway. This project utilizes The Cancer Genome Atlas (TCGA) to correlate clinical trial data and biomarker studies. Jordan's work aims to describe the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of each agent.